Kohshin Washiyama
Fukushima, 9601295, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Production of 211At and automated radiosynthesis of [211At]MABG via electrophilic astatodesilylation.
Journal: EJNMMI radiopharmacy and chemistry
Published: June 15, 2025
Evaluation of an 211At-labeled RGD peptide in an orthotopic glioblastoma model by targeted alpha therapy.
Journal: Nuclear medicine and biology
Published: June 12, 2025
Engineering a Radiohybrid PSMA Ligand with an Albumin-Binding Moiety and Pharmacokinetic Modulation via an Albumin-Binding Competitor for Radiotheranostics.
Journal: Molecules (Basel, Switzerland)
Published: June 02, 2025
New Investment for Theranostics in Europe
Journal: Kaku igaku. The Japanese journal of nuclear medicine
Published: April 02, 2025
In Vivo Stability Improvement of Astatobenzene Derivatives by Introducing Neighboring Substituents.
Journal: Journal of medicinal chemistry
Published: January 06, 2025
Long-Term Therapeutic Effects of 225Ac-DOTA-E[c(RGDfK)]2 Induced by Radiosensitization via G2/M Arrest in Pancreatic Ductal Adenocarcinoma.
Journal: Pharmaceutics
Published: November 29, 2024
Combination therapy of an 211At-labeled RGD peptide and immune checkpoint blockade to enhance antitumor efficacy.
Journal: European journal of nuclear medicine and molecular imaging
Published: October 25, 2024
In vivo-stable bis-iminobiotin for targeted radionuclide delivery with the mutant streptavidin.
Journal: Bioorganic & medicinal chemistry letters
Published: April 12, 2024
Optimizing the pharmacokinetics of an 211At-labeled RGD peptide with an albumin-binding moiety via the administration of an albumin-binding inhibitor.
Journal: European journal of nuclear medicine and molecular imaging
Published: January 06, 2024
Development of probes for radiotheranostics with albumin binding moiety to increase the therapeutic effects of astatine-211 (211At).
Journal: European journal of nuclear medicine and molecular imaging
Published: July 01, 2023
Astatine-211-labeled aza-vesamicol derivatives as sigma receptor ligands for targeted alpha therapy.
Astatine-211-labeled aza-vesamicol derivatives as sigma receptor ligands for targeted alpha therapy.
Journal: Nuclear medicine and biology
Published: May 08, 2023
Evaluation of Aminopolycarboxylate Chelators for Whole-Body Clearance of Free 225Ac: A Feasibility Study to Reduce Unexpected Radiation Exposure during Targeted Alpha Therapy.
Journal: Pharmaceutics
Published: September 09, 2021
Last Updated: 09/26/2026